159 related articles for article (PubMed ID: 24124001)
1. TGFBR3 co-downregulated with GATA3 is associated with methylation of the GATA3 gene in bladder urothelial carcinoma.
Liu XL; Xue BX; Lei Z; Yang DR; Zhang QC; Shan YX; Zhang HT
Anat Rec (Hoboken); 2013 Nov; 296(11):1717-23. PubMed ID: 24124001
[TBL] [Abstract][Full Text] [Related]
2. Dual role of TGFBR3 in bladder cancer.
Liu XL; Xiao K; Xue B; Yang D; Lei Z; Shan Y; Zhang HT
Oncol Rep; 2013 Sep; 30(3):1301-8. PubMed ID: 23835618
[TBL] [Abstract][Full Text] [Related]
3. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.
Cooper SJ; Zou H; Legrand SN; Marlow LA; von Roemeling CA; Radisky DC; Wu KJ; Hempel N; Margulis V; Tun HW; Blobe GC; Wood CG; Copland JA
Oncogene; 2010 May; 29(20):2905-15. PubMed ID: 20208565
[TBL] [Abstract][Full Text] [Related]
4. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
5. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer.
Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK
Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091
[TBL] [Abstract][Full Text] [Related]
6. GATA3 expression in sarcomatoid urothelial carcinoma of the bladder.
Fatima N; Osunkoya AO
Hum Pathol; 2014 Aug; 45(8):1625-9. PubMed ID: 24824028
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
8. p15(INK4b) in bladder carcinomas: decreased expression in superficial tumours.
Le Frère-Belda MA; Cappellen D; Daher A; Gil-Diez-de-Medina S; Besse F; Abbou CC; Thiery JP; Zafrani ES; Chopin DK; Radvanyi F
Br J Cancer; 2001 Nov; 85(10):1515-21. PubMed ID: 11720438
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
[TBL] [Abstract][Full Text] [Related]
10. Transitional cell carcinomas and nonurothelial carcinomas of the urinary bladder differ in the promoter methylation status of the caveolin-1, hDAB2IP and p53 genes, but not in the global methylation of Alu elements.
Kunze E; Von Bonin F; Werner C; Wendt M; Schlott T
Int J Mol Med; 2006 Jan; 17(1):3-13. PubMed ID: 16328005
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
12. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic regulation of vascular endothelial growth factor a dynamic expression in transitional cell carcinoma.
Ping SY; Shen KH; Yu DS
Mol Carcinog; 2013 Jul; 52(7):568-79. PubMed ID: 22392726
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series.
Raspollini MR; Sardi I; Giunti L; Di Lollo S; Baroni G; Stomaci N; Menghetti I; Franchi A
Hum Pathol; 2011 Aug; 42(8):1149-58. PubMed ID: 21334719
[TBL] [Abstract][Full Text] [Related]
15. Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder.
Xuan Y; Kim S; Lin Z
J Cancer Res Clin Oncol; 2011 Jan; 137(1):49-54. PubMed ID: 20217126
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Duarte-Pereira S; Paiva F; Costa VL; Ramalho-Carvalho J; Savva-Bordalo J; Rodrigues A; Ribeiro FR; Silva VM; Oliveira J; Henrique R; Jerónimo C
Eur J Cancer; 2011 May; 47(7):1106-14. PubMed ID: 21273058
[TBL] [Abstract][Full Text] [Related]
17. TGFBR3 loss and consequences in prostate cancer.
Sharifi N; Hurt EM; Kawasaki BT; Farrar WL
Prostate; 2007 Feb; 67(3):301-11. PubMed ID: 17192875
[TBL] [Abstract][Full Text] [Related]
18. GATA3 expression in paragangliomas: a pitfall potentially leading to misdiagnosis of urothelial carcinoma.
So JS; Epstein JI
Mod Pathol; 2013 Oct; 26(10):1365-70. PubMed ID: 23599157
[TBL] [Abstract][Full Text] [Related]
19. SOX4 expression levels in urothelial bladder carcinoma.
Gunes S; Yegin Z; Sullu Y; Buyukalpelli R; Bagci H
Pathol Res Pract; 2011 Jul; 207(7):423-7. PubMed ID: 21680105
[TBL] [Abstract][Full Text] [Related]
20. α4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients.
Liu J; Cai M; Chen J; Liao Y; Mai S; Li Y; Huang X; Liu Y; Zhang J; Kung H; Zeng Y; Zhou F; Xie D
Eur J Cancer; 2014 Mar; 50(4):840-51. PubMed ID: 24388773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
